Gammacan retains Global Markets Capital to pursue partnering opportunities

By Angela McDaniels

Seattle, Feb. 3 - Gammacan International said it has engaged investment bank Global Markets Capital Corp. to help the company form partnerships with leaders in the blood, plasma and IVIg markets.

"We believe that the development of IVIg-based products for the treatment of metastatic cancer have advanced to a stage that Gammacan is ready to explore various options of key synergistic 'partnerships' with IVIg manufacturers, plasma collectors and other players in the plasma industry," chief executive officer Vered Caplan said in a company news release.

"We look forward to supporting Gammacan through strategic transactions that will further the company's efforts to develop and commercialize its products and that will provide them with greater exposure in the capital markets," Global Markets Capital president Mark R. Saunders said in the release.

Gammacan is a Givat Shmuel, Israel-based company focused on the commercialization of an anticancer immunotherapy based on IVIg, a human plasma-based product currently used to treat a variety of immune deficiencies and autoimmune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.